VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+3.91%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$245M
AUM Growth
+$31M
(+15%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
12.58%
Top 10 Holdings %
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49
Top Buys
| 1 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
$1.88M |
| 2 |
DocuSign
DOCU
|
$1.49M |
| 3 |
United Airlines
UAL
|
$1.47M |
| 4 |
Fortinet
FTNT
|
$1.35M |
| 5 |
Spotify
SPOT
|
$1.34M |
Top Sells
| 1 |
Applovin
APP
|
$1.45M |
| 2 |
Expedia Group
EXPE
|
$1.04M |
| 3 |
KKR & Co
KKR
|
$976K |
| 4 |
CME Group
CME
|
$974K |
| 5 |
Corpay
CPAY
|
$948K |
Sector Composition
| 1 | Financials | 29.48% |
| 2 | Technology | 14.86% |
| 3 | Healthcare | 14.81% |
| 4 | Industrials | 11.61% |
| 5 | Consumer Discretionary | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
BioMarin Pharmaceuticals
BMRN
$11.1B
| $347K | 0.14% |
5,277
+1,367
| +35% | +$89.9K |
|
202
BridgeBio Pharma
BBIO
$10.2B
| $347K | 0.14% |
12,637
+1,280
| +11% | +$35.1K |
|
203
BioCryst Pharmaceuticals
BCRX
$1.74B
| $346K | 0.14% |
46,007
-6,858
| -13% | -$51.6K |
|
204
Day One Biopharmaceuticals
DAWN
$773M
| $346K | 0.14% |
27,296
+1,805
| +7% | +$22.9K |
|
205
Biogen
BIIB
$20.6B
| $344K | 0.14% |
2,251
+843
| +60% | +$129K |
|
206
Dynavax Technologies
DVAX
$1.18B
| $344K | 0.14% |
26,917
-506
| -2% | -$6.46K |
|
207
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $343K | 0.14% |
17,361
-195
| -1% | -$3.86K |
|
208
TG Therapeutics
TGTX
$5.11B
| $343K | 0.14% |
11,393
-8,258
| -42% | -$249K |
|
209
Zai Lab
ZLAB
$3.42B
| $343K | 0.14% |
13,086
-3,641
| -22% | -$95.4K |
|
210
Mirum Pharmaceuticals
MIRM
$3.82B
| $342K | 0.14% |
8,270
-4,074
| -33% | -$168K |
|
211
Sarepta Therapeutics
SRPT
$1.96B
| $342K | 0.14% |
2,809
+174
| +7% | +$21.2K |
|
212
United Therapeutics
UTHR
$18.1B
| $341K | 0.14% |
967
-178
| -16% | -$62.8K |
|
213
Incyte
INCY
$16.9B
| $341K | 0.14% |
4,937
-317
| -6% | -$21.9K |
|
214
Apellis Pharmaceuticals
APLS
$3.55B
| $341K | 0.14% |
10,680
+2,942
| +38% | +$93.9K |
|
215
Immunocore
IMCR
$1.87B
| $340K | 0.14% |
11,536
+3,238
| +39% | +$95.5K |
|
216
Travere Therapeutics
TVTX
$1.93B
| $340K | 0.14% |
19,523
-25,967
| -57% | -$452K |
|
217
Moderna
MRNA
$9.78B
| $340K | 0.14% |
8,166
+5,898
| +260% | +$245K |
|
218
Ardelyx
ARDX
$1.57B
| $338K | 0.14% |
66,728
+15,981
| +31% | +$81K |
|
219
Regeneron Pharmaceuticals
REGN
$60.8B
| $336K | 0.14% |
472
+151
| +47% | +$108K |
|
220
Alnylam Pharmaceuticals
ALNY
$59.2B
| $336K | 0.14% |
1,426
-632
| -31% | -$149K |
|
221
Insmed
INSM
$30.7B
| $335K | 0.14% |
4,853
-491
| -9% | -$33.9K |
|
|
SAGE
222
DELISTED
Sage Therapeutics
SAGE
| $335K | 0.14% |
61,668
+33,029
| +115% | +$179K |
|
223
Theravance Biopharma
TBPH
$703M
| $333K | 0.14% |
35,426
-2,960
| -8% | -$27.9K |
|
224
PTC Therapeutics
PTCT
$4.55B
| $333K | 0.14% |
7,383
-1,542
| -17% | -$69.6K |
|
225
Amgen
AMGN
$153B
| $333K | 0.14% |
1,276
+173
| +16% | +$45.1K |
|